Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Show Only Open Trials
1.
Gilead 0119: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Previously Treated Chronic Lymphocytic Leukemia (CLL)
- Protocol ID: Gilead 0119
2.
A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma
- Study Status: Open to Enrollment
- Sponsor: Memorial Sloan-Kettering Cancer Center
- Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
3.
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies
- Study Status: Open to Enrollment
- Sponsor: OncoMed
- Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
- Protocol ID: 52M51-001
4.
A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients with CLL
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated CLL
5.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Patients with Previously Treated Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Gilead Sciences, Inc.
- Disease Status and/or Stage: Previously Treated Chronic Lymphocytic Leukemia (CLL)
- Protocol ID: 0116
